garutadustat
AssetAlso ISM5411
Inhibits PHD1/2, stabilizing HIFα to promote epithelial barrier healing and reduce proinflammatory cytokine expression.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- EGLN1
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2Inflammatory bowel disease
Phase 2, insilico.com, 10 Oct 2026
Ulcerative colitis
Phase 2, Recruiting, NCT07265570, clinicaltrials.gov, 8 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors5
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.